What do systematic reviews say?

Allopurinol 100‐300 mg daily vs febuxostat 80 mg daily

Allopurinol 100‐300 mg daily showed no clear difference in serious adverse effects compared with febuxostat 80 mg daily (moderate certainty).

• Allopurinol for chronic gout 2014 · Cochrane Headline outcomes only
  RR 1.13 [0.71, 1.82]
  3 studies · 2556 participants
  Moderate

Allopurinol vs benzbromarone

The review found no eligible studies for this question.

• Allopurinol for chronic gout 2014 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Aquatic exercise for the treatment of knee and hip osteoarthritis 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Calcium channel blockers vs placebo

• Calcium channel blockers for primary and secondary Raynaud's phenomenon 2017 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported